Women with psychiatric disorders represent an at-risk population for premature delivery and other obstetrical complications. This study assesses the association between omega-3 fatty acid use and length of gestation. Â In an unadjusted model, there was [...]
Augmentation strategies can be used to optimize response in patients with major depressive disorder (MDD) who have not responded adequately to antidepressant monotherapy; however, we have no data on the use of adjunctive treatments in women with postpartum depression (PPD).  A recent study tested the effectiveness of antidepressant augmentation with aripiprazole (Abilify) in a cohort of 10 women with onset of a depression within 3 months of the birth of a healthy, close-to-term baby.
A recent study from Canada has observed higher rates of depression in mothers who have children after the age of 40. The prevalence of depression after delivery was about threefold higher in women aged 40 to 44 years as compared to women aged 30 to 35 years. This relationship was even stronger after controlling for potential confounders, including education level, marital status, and chronic illness (adjusted OR 3.72; 95% CI 2.15 to 6.41).
With the advent of the newer, atypical antipsychotic medications, patients with psychotic disorders have been able to achieve greater symptom control with less disabling side effects. For women with schizophrenia, there has also been an increase in fertility rates over the last decade. Previous studies have suggested that women with schizophrenia, as compared to women with no psychiatric illness, are at increased risk for pregnancy and delivery complications, including low birthweight, intrauterine growth restriction, and preterm birth. However, most of these studies occurred at a time when the women were treated with older antipsychotic medications, and we cannot assume that these findings are relevant now, when women with schizophrenia are more commonly treated with the newer atypical antipsychotics and have much better control of their symptoms.
Many women report cognitive difficulties -- forgetfulness, distractibility, feeling foggy ---during the transition to menopause. While much attention has been devoted to the treatment of vasomotor symptoms, such as hot flashes or night sweats, less [...]
Maternal psychiatric illness can profoundly affect how a mother interacts with her child and is a risk factor for impaired mother-infant bonding, which may include a spectrum of difficulties: decreased maternal affective involvement, increased irritability, [...]
Cognitive Behavioral Therapy or CBT is a type of psychotherapy that has been shown to be effective for the treatment of depression, anxiety, and sleep problems. Recently, several randomized controlled trials have demonstrated that CBT is effective for managing vasomotor symptoms in menopausal women.
Here's a new way to look at hot flashes. How much do they cost our society in terms of additional health care and lost productivity?
All women are at risk for postpartum depression (PPD), and there is growing evidence to suggest that poor sleep during pregnancy and the postpartum period may be a risk factor for the development of depression. [...]
The Edinburgh Postnatal Depression Scale (EPDS) was modified by adding lifetime PND screening questions, assessing worst episode, and symptom timing of onset, in order to assess the lifetime prevalence of perinatal depression. Subjects from the [...]
